

and IRVING SCHULMAN. Dept. of Ped., The Abraham Lincoln Sch. of Med., Univ. of Illinois, Chicago, IL.

Platelet aggregation was studied in platelet-rich plasma (PRP) prepared from samples of maternal and cord blood taken immediately after delivery. When mothers had received no drugs for analgesia, adenosine diphosphate- and collagen-induced aggregation curves of platelets from the infants and from the mothers were virtually identical and were within the normal range. When mothers (18) had received drugs (acetylsalicylic acid, promethazine, alphaprodine and meperidine) prior to delivery, 17 of 18 of the cord blood samples showed a marked decrease in collagen-induced platelet aggregation. By contrast, in paired PRP samples from these mothers abnormalities of collagen-induced platelet aggregation were found in only 25%, and these changes were minimal. These findings suggested that the infants' platelets were more susceptible to the drug-induced suppression of collagen aggregation than were platelets of the mothers. Dose response curves to promethazine added *in vitro* demonstrated a markedly increased susceptibility of newborn platelets when compared with those of the mothers. These results indicate that a variety of drugs given to mothers before delivery may alter platelet aggregation of the newborn infants, resulting in significant impairment of the platelet-mediated phase of hemostasis.

- 34 *Plasma 17-OH Progesterone in Maternal and Umbilical Cord Plasma in Children, and in Congenital Adrenal Hyperplasia (CAH): Application to Neonatal Diagnosis of CAH.* MORRIS R. JENNER, MELVIN M. GRUMBACH and SELNA L. KAPLAN. Univ. of California, San Francisco Med. Center, San Francisco, CA.

The concentration of plasma 17 α -OH progesterone (17-OHP) was determined utilizing a ligand binding radioassay at delivery in maternal (8) and umbilical venous (8) blood and in the blood of newborn infants (8), children (12), adult males (13), and pre- and post-treatment in 6 patients with CAH. Adult male values (mean = 0.106 μ g/100 ml) are in agreement with the data of STROTT *et al.* [J. clin. Invest. 48: 930, 1969]. Mean concentration in maternal plasma at delivery was 0.365 μ g/100 ml and in cord plasma 1.64 μ g/100 ml. Twelve newborns (age 1-7 days) demonstrated a rapid fall in concentration of plasma 17-OHP within the first day of life (range <0.100-0.125 μ g/100 ml). Twelve normal children (age 5-11 years) had a mean level of 0.036 μ g/100 ml (range 0.016-0.059). In contrast, 5 children (age 4 days-7 years) and an adult (age 26 years) with untreated CAH had a mean value of 12.8 μ g/100 ml (range 2.4-33.0 μ g/100 ml). A 4-day-old female pseudohermaphrodite, the youngest subject with CAH, had a plasma 17-OHP of 5.7 μ g/100 ml. In 1 infant with CAH the concentration of plasma 17-OHP fell from 11.4 μ g% to 0.12 μ g% on cortisone therapy, and in a female, age 2-⁷/₁₂ years, from 33.0 μ g% to 0.148 μ g/100 ml. In 4 patients with CAH, changes in plasma testosterone paralleled those in 17-OHP. The results suggest that estimation of plasma 17-OHP in a 0.2 ml sample by this method permits rapid identification of the 21 hydroxylase deficiency form of CAH by the 2nd day of life and is useful in assessing the adequacy of glucocorticoid treatment. The high concentration of plasma 17-OHP in cord blood is attributable to the capacity of the placenta to convert maternal and fetal steroid precursors to 17-OHP.

INDEX OF ABSTRACTS

(Numbers following entries refer to abstract number)

- | | | |
|--------------------------------|-----------------------------------|-----------------------------------|
| AAGENAES, O. 23 | central nervous system 28, 31 | development 31 |
| adenoids 1 | CHABOT, A. 10 | developmental pharmacology 33 |
| ADRIANZEN, T. B. 16 | CHACKO, C. M. 18 | diagnosis, prenatal 4 |
| amniocentesis 25 | CHAPMAN, E. M. 14 | DiMAURO, S. 3 |
| amniotic fluid 4 | child care 10, 13 | DORFMAN, A. 4 |
| antibody, rubella 7 | children 26 | |
| ARBIT, J. 28 | cholestasis 23 | Embryo, mouse 17 |
| | chromosomes 25 | endocardial fibroelastosis 24 |
| BAKER, L. 22 | COCHRAN, W. 9 | enzyme 22 |
| BEAUDRY, P. H. 27 | COHEN, M. M. 17 | erythroblastosis 9 |
| BECK, J. 26 | community health program 10 | erythrocytes 6 |
| BERLIN, C. M. 25 | CONDON, A. 3 | exfoliation 29 |
| bile 23 | congenital adrenal hyperplasia 34 | |
| BLANC, W. 15 | congenital anomalies 25 | Fertilization, <i>in vitro</i> 17 |
| BLONSKY, E. R. 28 | congenital rubella 7 | fetal transfusions 9 |
| blood 33 | COOPER, L. Z. 7 | fetus 3 |
| BRADLEY, K. H. 32 | CORBY, D. G. 33 | fibrinolysis 5 |
| brain 31 | CRAWFORD, J. D. 14 | fibrin split products 5 |
| | CUDERMAN, B. 23 | FLORMAN, A. L. 7 |
| CALDWELL, B. M. 13 | cystine 32 | fructose-1,6-diphosphatase 22 |
| carbohydrate metabolism 11, 22 | cystinosis 32 | |
| care, pediatric 2 | | Galactose 1-phosphate uridyl |
| CASSELL, S. 28 | deafness 7 | transferase 18 |
| cell hybridization 18 | deoxyadenosyl-B ₁₂ 12 | genetic disease 12, 21 |

- GIBSON, M.S. 33
 GINSBERG-FELLNER, F. 11
 GLASGOW, L.A. 29
 glomerulonephritis 19
 gluconeogenesis 22
 glucose metabolism 31
 glycolysis 3
 GOODMAN, J.R. 26
 GORDIS, L. 2
 GRAHAM, G.G. 16
 growth 16
 growth failure 21
 GRUMBACH, M.M. 34
- HALSTEAD, S.B. 8
 HAYEK, A. 14
 hemoglobin SS disease 6
H. influenza, type b 20
 HORSTMANN, D.M. 8
 Hunter's syndrome 4
 Hurler's syndrome 4
 21-hydroxylase deficiency 34
 hypoglycemia 22
 hypoxemia 30
- Immunity 1, 7, 8, 20
 immunization 20
 inanition 31
 infant 22, 25
 infant mortality rate 10
 infants 9, 27, 28, 33, 34
 infants, low birth weight 15
 infection, intrauterine 15
 intragenic complementation 18
 intrauterine blood transfusion
 9, 28
 intravascular coagulation 5
- JACOBSON, C.B. 4, 25
 JANKUS, E.F. 24
 JENNER, M.R. 34
- KAPLAN, S.L. 34
 KAZEMI, H. 30
 kidney 5, 19, 26
 KNITTLE, J.L. 11
 KRIVIT, W. 23
 KRUGMAN, S. 7
 KUPLIĆ, L.S. 5
- LANGE, K. 19
 LEONARD, A.S. 23
 LIEBHABER, H. 8
 lipocytes 11
 β -lipoproteinemia, hypo 21
 liver 22, 23
 lung 27
 lung function 30
 lymphedema 23
 lymph flow, hepatic 23
- lysergic acid diethylamide 25
- MAHONEY, M.J. 12
 malnutrition 16
 MARKOWITZ, M. 2
 MATALON, R. 4
 MELISH, M.E. 29
 MELLMAN, W.J. 3
 metabolic acidosis 22
 methylmalonicaciduria 12
 methylmalonyl-CoA mutase 12
 monosodium glutamate 11
 mucopolysaccharides 4
 MUKHERJEE, A. 17
 myocarditis 24
- NADLER, H.L. 18
 NAEYE, R. 15
 nephritis 26
 nephritogenic antigen 19
 newborn 33
 newborns 20
 NOGRADY, B. 27
 NOREN, G.R. 24
- Obesity 11
 OGRA, P.L. 1
 OH, W. 28
 OLSON, W.H. 32
 OSKI, F.A. 3
 OUTERBRIDGE, E.W. 27
 oxidative metabolism 31
- PARKE, J.C., Jr. 20
 PARTIN, J.C. 21
 PEARSON, H.A. 6
 PIEL, C.F. 26
 placenta 33, 34
 platelets 33
 poliovirus 1
 poverty 15
 pregnancy 25
 prematurity 15
 17-OH progesterone 34
- Race 15
 RACHMELER, M. 18
 radioiodine 14
 renal disease 26
 respiratory distress syndrome 27
 Rh erythroblastosis 28
 rheumatic fever 2
 RICHMOND, J.B. 13
 RISEBOROUGH, E.P. 30
 ROBBINS, J.B. 20
 RODRIGUES, L.P. 20
 ROSENBERG, D.M. 8
 ROSENBERG, L.E. 12
 round heart disease 24
 rubella 8
- rubella vaccine 8
 rubella virus vaccine 7
- SAGEL, I. 19
 SATTERTHWAITTE, H.S. 31
 SCHEINMAN, J.I. 5
 SCHNEERSON, R. 20
 SCHUBERT, W.K. 21
 SCHULHOFF, C. 9
 SCHULMAN, I. 33
 SCHULMAN, J.D. 32
 SCHWARTZ, A.D. 6
 scoliosis 30
 SEEGMILLER, J.E. 32
 SHANNON, D.C. 30
 SHARP, H.L. 23
 sickle cell anemia 6
 SIGSTAD, H. 23
 skeletal development 11
 SMITH, A.L. 31
 SOKOLOFF, L. 31
 SPENCER, R.P. 6
 spleen 6
 STALEY, N.A. 24
 STAMBAUGH, M.C. 12
 staphylococcal scalded skin
 syndrome 29
 staphylococcus 29
 STARK, A. 9
 STERN, L. 27
 STEVENSON, J.E. 24
 STEHM, E.R. 5
 streptococcus 19
 systemic lupus erythematosus 26
- Thyroid cancer 14
 thyrotoxicosis 14
 tonsils 1
 toxin 29
 TRYGSTAD, C.W. 5
 TURNER, M.D. 29
 TY, A. 19
- UEHLING, D.T. 5
 umbilical cord 34
- Vaccine, *H. influenza* type b 20
 VALENCA, L.M. 30
 virus disease 26
 vitamin B₁₂ 12
- White villus disease 21
 WINEGRAD, A.I. 22
 WOLFSON, S.L. 6
 WONG, V.G. 32
- ZELSON, J.H. 6
 ZIRBEL, C.L. 33
 ZIRING, P.R. 7